Results 261 to 270 of about 3,422,852 (337)
High‐throughput microfluidic real‐time PCR as a promising tool in disease ecology
This work highlights the diversity of disease ecology questions Htrt PCR could contribute to addressing in a given host–pathogen ecosystem. This tool could be used to answer a broad set of basic and applied questions in animal ecology, notably by providing a way to address issues involving communities of hosts and communities of pathogens.
Tristan Bralet+15 more
wiley +1 more source
Dietary L-arabinose-induced gut dysbiosis exacerbates Salmonella infection outcome. [PDF]
Yu J+9 more
europepmc +1 more source
This research reveals the gut microbiota‐mediated severe foraging environment adaptation of wild small ruminants in the Three‐River‐Source National Park. Unlike Tibetan sheep (TS), blue sheep (PN and Tibetan antelope (TA) often grazed low‐quality herbage in a wildness environment, and the higher microbial diversity and resilient network characteristics
Hongjin LIU+11 more
wiley +1 more source
INFECTION OF SALMONELLA ENTERITIDIS WITH PHAGES FROM SALMONELLA TYPHIMURIUM
Yasuki Hattori
openalex +2 more sources
Host species emerge as a significant contributor to interspecies variations in the gut microbiota of desert‐dwelling amphibians and reptiles, illustrating phylosymbiosis among the studied species. Geographical factors partially account for interpopulation variations in the gut microbiota of Bufotes pewzowi and Teratoscincus przewalskii, with parallel ...
Wei Zhu+8 more
wiley +1 more source
Esculetin Combats Multidrug-Resistant Salmonella Infection and Ameliorates Intestinal Dysfunction via the Nrf2 Pathway. [PDF]
Xu W, Ding W, Jia L, Zhu K, Luo Q.
europepmc +1 more source
Meles anakuma and Felis catus Dying of Salmonella enteritidis infection.
Keiji Matsuoka+2 more
openalex +2 more sources
Anti‐KIT Barzolvolimab for Chronic Spontaneous Urticaria
We compared the efficacy and safety of four doses of barzolvolimab compared to placebo in reducing symptoms of chronic spontaneous urticaria in a randomized, controlled trial. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks.
Marcus Maurer+11 more
wiley +1 more source